Cervical Cancer: a Meta-analysis, Therapy and Future of Nanomedicine

Overview

Journal Ecancermedicalscience

Specialty Oncology

Date 2020 Nov 4

PMID 33144879

Citations 16

Authors

Jeaneen Venkatas

Moganavelli Singh

Affiliations

Soon will be listed here.

Abstract

Cervical cancer is one of the leading causes of female death, with an annual mortality rate exceeding 200,000 in developing communities. Despite the past decade bearing witness to a reduction in cervical cancer cases throughout developed countries, the prevalence in developing countries continues to rapidly rise. The increase in cervical cancer cases is attributed to the lack of financial resources and the unavoidable risk factors of the disease. Traditional means of anticancer therapy are compromised by reduced drug potency, non-specificity, negative side effects and the development of multiple drug resistance (MDR), which leads to a decrease in the long-term anticancer therapeutic efficacy. Recent advances in nanomedicine have elucidated the potential of nanoparticles to reduce the side effects and improve the survival rate of patients, by enhancing selective delivery and uptake of photosensitive, therapeutic and genetic material to cervical cancer cells, thereby enhancing antitumour efficiency. This review paper analyses the risk factors and epidemiology of cervical cancer globally, especially in developing communities, whilst demonstrating the enhanced anticancer treatment using selected nanoparticles.

Citing Articles

Exploring the Intricacies of Cervical Intraepithelial Neoplasia and Its Connection with HPV: A Narrative Review.

Karimi P, Reza Hosseini S, Mousavian Hiagh Z, Aboulhassanzadeh S, Asghari N, Aghazadeh H Iran J Public Health. 2025; 53(12):2671-2682.

PMID: 39759206 PMC: 11693788.

Nanotheranostics for gynecological cancers: a path forward for Africa.

Aza M, Suberu A, Balogun M, Adegbola G, Sankoh M, Oyediran T Med Oncol. 2024; 42(1):34.

PMID: 39704911 DOI: 10.1007/s12032-024-02582-4.

Cervical cancer: Challenges and prevention strategies: A narrative review.

Tsige A, Beyene D Health Sci Rep. 2024; 7(6):e2149.

PMID: 38826620 PMC: 11139676. DOI: 10.1002/hsr2.2149.

Copolymer-Green-Synthesized Copper Oxide Nanoparticles Enhance Folate-Targeting in Cervical Cancer Cells In Vitro.

Jagaran K, Singh M Polymers (Basel). 2023; 15(10).

PMID: 37242968 PMC: 10223539. DOI: 10.3390/polym15102393.

Genotyping and Phylogenetic Analysis of Human Papillomaviruses in Formalin Fixed Paraffin Embedded Sections from Cervical Lesions in Duhok-Iraq.

Othman A, Goreal A, Pity I Asian Pac J Cancer Prev. 2023; 24(4):1313-1319.

PMID: 37116154 PMC: 10352747. DOI: 10.31557/APJCP.2023.24.4.1313.

References

Saglam A, Usubutun A, Dolgun A, Mutter G, Salman M, Kurtulan O . Diagnostic and Treatment Reproducibility of Cervical Intraepithelial Neoplasia / Squamous Intraepithelial Lesion and Factors Affecting the Diagnosis. Turk Patoloji Derg. 2017; 1(1):177-191. DOI: 10.5146/tjpath.2017.01400. View

Hill A, Chen M, Chen C, Pfeifer B, Jones C . Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors. Trends Biotechnol. 2016; 34(2):91-105. PMC: 5800990. DOI: 10.1016/j.tibtech.2015.11.004. View

Takekuma M, Kasamatsu Y, Kado N, Kuji S, Tanaka A, Takahashi N . The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review. J Obstet Gynaecol Res. 2017; 43(4):617-626. DOI: 10.1111/jog.13282. View

Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N . Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta. 2013; 1833(12):3448-3459. DOI: 10.1016/j.bbamcr.2013.06.001. View

Kou J, Dou D, Yang L . Porphyrin photosensitizers in photodynamic therapy and its applications. Oncotarget. 2017; 8(46):81591-81603. PMC: 5655312. DOI: 10.18632/oncotarget.20189. View

Rivera-Colon G, Chen H, Niu S, Lucas E, Holloway S, Carrick K . Cervical Adenocarcinoma: Histopathologic Features From Biopsies to Predict Tumor Behavior. Am J Surg Pathol. 2019; 44(2):247-254. DOI: 10.1097/PAS.0000000000001379. View

Fader A . Surgery in Cervical Cancer. N Engl J Med. 2018; 379(20):1955-1957. PMC: 6989030. DOI: 10.1056/NEJMe1814034. View

Adebamowo S, Dareng E, Famooto A, Offiong R, Olaniyan O, Obende K . Cohort Profile: African Collaborative Center for Microbiome and Genomics Research's (ACCME's) Human Papillomavirus (HPV) and Cervical Cancer Study. Int J Epidemiol. 2017; 46(6):1745-1745j. PMC: 5837640. DOI: 10.1093/ije/dyx050. View

Hofsjo A, Bohm-Starke N, Blomgren B, Jahren H, Steineck G, Bergmark K . Radiotherapy-induced vaginal fibrosis in cervical cancer survivors. Acta Oncol. 2017; 56(5):661-666. DOI: 10.1080/0284186X.2016.1275778. View

10.

Pita R, Ehmann F, Papaluca M . Nanomedicines in the EU-Regulatory Overview. AAPS J. 2016; 18(6):1576-1582. DOI: 10.1208/s12248-016-9967-1. View

11.

Lechanteur A, Furst T, Evrard B, Delvenne P, Piel G, Hubert P . Promoting Vaginal Distribution of E7 and MCL-1 siRNA-Silencing Nanoparticles for Cervical Cancer Treatment. Mol Pharm. 2017; 14(5):1706-1717. DOI: 10.1021/acs.molpharmaceut.6b01154. View

12.

Sun Q, Barz M, De Geest B, Diken M, Hennink W, Kiessling F . Nanomedicine and macroscale materials in immuno-oncology. Chem Soc Rev. 2018; 48(1):351-381. PMC: 7115880. DOI: 10.1039/c8cs00473k. View

13.

Sriplung H, Singkham P, Iamsirithaworn S, Jiraphongsa C, Bilheem S . Success of a cervical cancer screening program: trends in incidence in songkhla, southern Thailand, 1989-2010, and prediction of future incidences to 2030. Asian Pac J Cancer Prev. 2014; 15(22):10003-8. DOI: 10.7314/apjcp.2014.15.22.10003. View

14.

Vordermark D . Radiotherapy of Cervical Cancer. Oncol Res Treat. 2016; 39(9):516-20. DOI: 10.1159/000448902. View

15.

Sugawara Y, Tsuji I, Mizoue T, Inoue M, Sawada N, Matsuo K . Cigarette smoking and cervical cancer risk: an evaluation based on a systematic review and meta-analysis among Japanese women. Jpn J Clin Oncol. 2018; 49(1):77-86. DOI: 10.1093/jjco/hyy158. View

16.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

17.

Jensen K, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer S . Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer. 2012; 108(1):234-9. PMC: 3553518. DOI: 10.1038/bjc.2012.513. View

18.

Chen J, Huang L, Lai H, Lu C, Fang M, Zhang Q . Methotrexate-loaded PEGylated chitosan nanoparticles: synthesis, characterization, and in vitro and in vivo antitumoral activity. Mol Pharm. 2013; 11(7):2213-23. DOI: 10.1021/mp400269z. View

19.

Asthana S, Busa V, Labani S . Oral contraceptives use and risk of cervical cancer-A systematic review & meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020; 247:163-175. DOI: 10.1016/j.ejogrb.2020.02.014. View

20.

Rohner E, Butikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J . Cervical cancer risk in women living with HIV across four continents: A multicohort study. Int J Cancer. 2019; 146(3):601-609. PMC: 6898726. DOI: 10.1002/ijc.32260. View